Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 4, 2005, Pages 556-562

  Kato, Mikio ^a   Sada, Toshio ^a   Mizuno, Makoto ^a   Kitayama, Ken ^a   Inaba, Toshimori ^a   Koike, Hiroyuki ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Antiatherogenic effect; AT1 receptor blocker; Combination therapy; HMG CoA reductase inhibitor; WHHL rabbit

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSINE DERIVATIVE; MONOCYTE CHEMOTACTIC PROTEIN 1; N EPSILON (CARBOXYMETHYL)LYSINE; OLMESARTAN; PRAVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HERITABILITY; HYPERLIPIDEMIA; IMMUNOHISTOLOGY; LIPID STORAGE; MACROPHAGE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; BLOOD PRESSURE; CHEMOKINE CCL2; CHOLESTEROL; DRUG THERAPY, COMBINATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MACROPHAGES; PRAVASTATIN; RABBITS; TETRAZOLES; TUNICA INTIMA;

EID: 26044452061     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000179434.18750.28     Document Type: Article

References (22)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
3. Kitamoto S, Nakano K, Hirouchi Y, et al. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates. Arterioscler Thromb Vasc Biol. 2004;24:1522-1528.
4. Chobanian AV, Haudenschild CC, Nickerson C, et al. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
5. Sugano M, Makino N, Yanaga T. The effect of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis. 1996;127:123-129.
6. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol. 1999;128:523-529.
7. Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 1999;12:28-34.
8. Hayek T, Attias J, Coleman R, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res. 1999;44:579-587.
9. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532-1541.
10. Keidar S, Attias J, Smith J, et al. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622-625.
11. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-677.
12. The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)-rationale design, and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol. 1990;66:315-322.
13. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
14. Kowala MC, Valentine M, Recce R, et al. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and eaptopril: ACE in atheromas provides cellular targets for captopril. J Cadiovasc Pharmacol. 1998;32:29-38.
15. Shiomi M, Ito T, Watanabe Y, et al. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine. Atherosclerosis. 1990;83:69-80.
16. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin 11 in atherosclerosis. Regul Pept. 2000;93:65-77.
17. Keidar S, Attias J, Heinrich R, et al. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis. 1999;146:249-257.
18. Nagai R, Ikeda K, Higashi T, et al. Hydroxyl radical mediates N epsilon-(carboxymethyl)lysine formation from Amadori product. Biochem Biophys Res Commun. 1997;234:167-172.
19. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003;14:1212-1222.
20. Fliser D, Buchholz K, Haller H. European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103-1107.
21. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin 11 receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478.
22. 1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-2134.